Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Albireo Exits NASH, But Has Best-In-Class IBAT Opportunity

Aug 21 2020

• By Joseph Haas

Autonomous self driving electric car change the lane and overtakes city vehicle 3d rendering — Exiting NASH, Albireo now will put full focus on pediatric cholestatic diseases

Related Content

NASH Companies Take The Stage At AASLD

Nov 15 2019

Mirum’s Long-Term Alagille Data Support Case For Early Filing

Nov 28 2019

Newly Hatched Mirum To Focus On Rare Liver Disease Candidates Shelved By Shire

Nov 07 2018

Albireo Making Headway In Rare Pediatric Liver Diseases With IBAT Inhibition

Oct 25 2017

Related Companies

Albireo Pharma Inc.

AstraZeneca PLC

Mirum Pharmaceuticals, Inc.

GSK plc

Additional Topics

Clinical Trials Business Strategies Companies Drug Approval Standards Pediatrics Rare Diseases Research & Development BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window